Including polymerase chain reaction in screening for hepatitis C virus RNA in blood donations is not cost-effective

Vox Sanguinis

Volumn 80, Issue 4, 2001, Pages 199-204

  Loubiere S ^a,c   Rotily, M ^a   Durand Zaleski, I ^b   Costagliola, D ^a  

^a INSERM   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c OBSERVATOIRE RÉGIONAL DE LA SANTÉ PROVENCE ALPES CÔTE D AZUR   (France)

Author keywords

Cost effectiveness; Hepatitis C; Residual risk; Screening; Transfusion

Indexed keywords

HEPATITIS C ANTIBODY; VIRUS RNA;

ANTIBODY SCREENING; ARTICLE; BLOOD DONOR; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FRANCE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCREENING TEST;

BLOOD DONORS; COST-BENEFIT ANALYSIS; HEPACIVIRUS; HEPATITIS C; HUMANS; MASS SCREENING; POLYMERASE CHAIN REACTION; RNA, VIRAL;

EID: 0035353401     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1423-0410.2001.00036.x     Document Type: Article

References (32)

1. Kuo G, Choo QI, Alter HJ, GitKnick G, Redeker A, Purcell R, Myamura T, Dienstag JL, Alter MJ, Stevens CE, Tegtmeier GE, Bonino F, Colombo M, Lee WS, Kuo C, Berger K, Shuster JR, Overby LR, Bradley DW, Houghton M: An assay for circulating antibodies to a major etiologic virus of human non-A non-B hepatitis. Science 1989; 244:362-367
2. Kleinman SH, Busch MP, Korelitz JJ, Schreiber G: The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection. Transfus Med 1997; 11:155-172
3. Barin F: Routine PCR screening of blood. Lancet 1999; 353:1799-1800
4. Roth WK, Weber M, Seifried E: Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus, and HIV-1 in a blood-bank setting. Lancet 1999; 29:1596-1601
5. Committee for Proprietary Medicinal Products C: The introduction of genomic amplification technology (GAT) for the detection of hepatitis C virus RNA in plasma pools (CPMP/BWP/390/97). Addendum to Note for Guidance on Plasma Derived Medicinal Products (CPMP/BWP/269/95). Paris, CPMP/BWP, 1997
6. Pillonel J, Saura C, Courouce AM: Prevalence of HIV, HTLV, and hepatitis B and C virus in blood donors in France. 1992-96. Transfus Clin Biol 1998; 5:305-312
7. Schreiber GB, Bush MP, Kleinman SH, Koreliz J, for the retrovirus epidemiology donor study: The risk of transmission-transmitted viral infections. N Engl JMed 1996; 334:1685-1690
8. Couroucé AM, Pillonel J: Estimation of risk of virus transmission in hepatitis B and C and human retrovirus via transfusion of labile blood derivatives. Transfus Clin Biol 1996; 3:858-862
9. Le Corfec E, Le Pont F, Tuewell HC, Rouzioux C, Costagliola D: Direct HIV testing in blood donations: Variation of the yield with detection threshold and pool size. Transfusion 1999; 39:1141-1144
10. Kim WR, Poterucha JJ, Gross JB, Dickson E, Evans W: Cost-effectiveness of 6 and 12-months of interferon-alpha treatment for chronic hepatitis C. Ann Intern Med 1997; 127:866-873
11. Aubert C, Colin C: Dépistage de l'Hépatite C Avant et Après Transfusion; Evaluation Médico-Économique des Stratégies de Dépistage des Hépatites C et Non-A, Non-B, Non-C Chez les Receveurs de Produits Sanguins Labiles. Lyon, Département d'Information Médicale, Hospices Civils de Lyon; sponsored by the Fonds d'Orientation à la Recherche en Transfusion Sanguine (FORTS), 1998
12. Mathoulin-Pelissier S, for the Centre National d'Hémovigilance: Etude sur les Receveurs et Produits Transfusés en France Métropolitaine (Study RECEPT). Bordeaux, Université Victor Segalen Bordeaux 2, 1998
13. Vamvakas EC, Taswell H: Mortality after blood transfusion. Transfus Med 1994; 8:267-280
14. Poynard T, Marcellin P, Lee SL, Niederau C, Minuk GS, Bain V, Heathcote J, Zeurem S, Trepo C, Albrech J: Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks for treatment of chronic hepatitis C virus. Lancet 1998; 352:1426-1432
15. McHutchison JG, Gordon SC, Schiff ER, Shiffman M, Lee W, Rustgi V, Goodman ZG, Ling MH, Cort S, Albrecht JK, for the Hepatitis interventional therapy group: Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339:1485-1492
16. Reichard O, Norkrans G, Fryden A, Braconier J, Sönnerborg A, Weiland O, and the Swedish study group: Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351:83-87
17. Sailly JC, Lebrun T, Coudeville L: Approche coût-efficacitė du dépistage des virus VIH, VIB, VHC, HTLV chez les donneurs de sang en France. Rev Epidemiol Sante Publique 1997; 45:131-141
18. Laupacis A, Feeny D, Detsky AS, Tugwell PX: Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1993; 148:927-929
19. Moatti JP: Ethical issues in the economic assessment of health care technologies. Health Care Anal 1999; 7:153-165
20. Tengs OT, Adams ME, Pliskin JS, Safran DG, Siegel JE, Weinstein AC, Graham JP: Five hundred life-saving interventions and their costeffectiveness. Risk Anal 1995; 15:369-390
21. Morishima C, Gretch DR. Clinical use of hepatitis C virus tests for diagnosis and monitoring during therapy; in Davis GL (ed.): Clinics in Liver Disease vol. 3. Philadelphia, W.B. Saunders. 1999:717-740.
22. Rotily M, Loubière S, Nixon J, Bourlière M, Halfon P, Moatti JP: Analyse socio-économique de différentes stratégies de dépistage de l'hépatite chronique C dans la population française. Gastroenterol Clin Biol 1997; 20:S33-S40
23. William AE, Thomson RA, Schreiber GB, Watanabe K, Bethel J, Lo A, Kleinman SH, Hollingsworth CG, Nemo GJ: Estimates of infectious disease risk factors in US blood donors. J Am Med Assoc 1997; 277:967-972
24. Courouce AM, Pillonel J, Saura C: Infections récentes par le virus de l'hépatite C chez les donneurs de sang et facteurs de risque. Bull Epidemiol Hebdo 1998; 4:13-14
25. Dodd RY, Aerle-Grasse JM, Stramer SL, Notari E: The yield of NAT for HIV and HCV RNA in a population of US voluntary donors. Transfusion 2000; 40:1S
26. Dore GJ, Kaldor J, McCaughan G: Systematic review of role of polymerase chain reaction in defining infectiousness among people infected with hepatitis C virus. Br Med J 1997; 315:333-337
27. Lefrère JJ: Biologie molėculaire et sécurité virale transfusionnelle. Transfus Clin Biol 1998; 5:22-38
28. Trinker M: False-positive diagnosis of tuberculosis with PCR. Lancet 1996; 348:1388
29. Warnock M: Some moral problems in medicine. Health Econ 1994; 3:297-300
30. Sicard D: The precaution principle and blood transfusion. Transfus Clin Biol 2000; 7:220-227
31. Fischhoff B, Lichtenstein S, Slovic P, Derby SL, Keeney RL: Acceptable Risk. Boston, Cambridge University Press, 1981
32. Kourilsky P, Viney G (eds): The Precaution Principle: Report to the Prime Minister (in French): Paris, Odile Jacob, 2000